Targeting Tumor Angiogenesis with the Selective VEGFR-3 Inhibitor EVT801 in Combination with Cancer Immunotherapy.
Paillasse MR, Esquerré M, Bertrand FA, Poussereau-Pomié C, Pichery M, Visentin V, Gueguen-Dorbes G, Gaujarengues F, Barron P, Badet G, Briaux A, Ancey PB, Sibrac D, Erdociain E, Özcelik D, Meneyrol J, Martin V, Gomez-Brouchet A, Selves J, Rochaix P, Battistella M, Lebbé C, Delord JP, Dol-Gleizes F, Bono F, Blanc I, Alam A, Hunneyball I, Whittaker M, Fons P.
Paillasse MR, et al. Among authors: briaux a.
Cancer Res Commun. 2022 Nov 29;2(11):1504-1519. doi: 10.1158/2767-9764.CRC-22-0151. eCollection 2022 Nov.
Cancer Res Commun. 2022.
PMID: 36970050
Free PMC article.